BASF Plant Science is a subsidiary of BASF in which all plant biotechnology activities are consolidated. The GmbH was founded in 1998 and employs approximately 700 people at 6 different locations worldwide. The headquarters of BASF Plant Science is located in Research Triangle Park (North Carolina, USA). Plant Science has research sites in the US, Canada and Europe. At these locations the company is mainly developing genetically modified seeds.

Valent U.S.A. LLC develops and markets biologically-based crop protection and enhancement solutions. Its products include herbicide, insecticide, fungicide and plant growth regulator products for agricultural, seed protection, and professional use. The company was founded in 1988 and is headquartered in Walnut Creek, CA.

BASF AB supplies raw materials to paper, chemicals, and construction industries. Its products include construction chemical, crop protection products, dispersions and pigments, plastics, polyurethane systems and coating products. The company was founded in 1953 and is headquartered in Göteborg, Sweden.

Jiangsu Chengxin Pharmaceutical Co. Ltd. engages in pharmaceutical preparations. The firm offers cosmetic, pharmaceutical, supplements, and coenzyme Ingredients. Its products include Praziquantel, Nicotinamide Mononucleotide, Nicotinamide Adenine Dinucleotide, reduced Nicotinamide Adenine Dinucleotide and Alanyl Glutamine. The company is headquartered in Nantong, China.

Syngenta AG is a global company that produces agrochemicals and seeds and is based in Basel, Switzerland. As a biotechnology company, it conducts genomic research. It was formed in 2000 by the merger of Novartis Agribusiness and Zeneca Agrochemicals. As of 2014 Syngenta is the world’s largest crop chemical producer As of 2009 it ranked third in seeds and biotechnology sales. Sales in 2015 were approximately US$13.4 billion, over half of which were in emerging markets. It is owned by ChemChina, a Chinese state-owned enterprise.

Plant Genetic Systems International, part of Bayer AG, is a Dutch company that provides biological products. The firm was founded by Daniel D. Adams.

Shaanxi Shenzhou Biotechnology Co., Ltd., established on 2000-06-15, Business scope includes biotechnology research and development,Technical Services,technical consulting,technology transfer;Technology research and development of bioengineering drugs,technical consulting,Technical Services,technology transfer;cosmetic,R&D of skin care products,Sales and technical consultation;the first sort,second category,Research and Development of Class III Medical Devices,Production(or commissioned processing)and sales;Health Management Consulting;food,Health products,drug sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

RespireRx Pharmaceuticals Inc. is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. All of the Company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress.

Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CART antibodies. .

Shaanxi Jiuzhou Biomedical Technology Group Co., Ltd., established on 2006-09-11, Business scope includes general items:R&D and application of cell technology;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Human stem cell technology development and application;Remote Health Management Services;Health Consulting Services(Does not include medical services);Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Biochemical product technology research and development;Pharmaceutical commissioned production;New material technology research and development;Sales of Class I Medical Devices;Production of Class I Medical Devices;Health Care Services(non-medical);brand management;business management;hospital management;sales agent;Conference and Exhibition Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Drug retail;pharmaceutical production;Cosmetic production;Drug import and export;Life beauty service;Production of Class II Medical Devices;Production of Class III Medical Devices;food production;food sales;Food Internet Sales;Health Supplies(non food)Production;Health Supplies(non food)Sales;Inspection and testing service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Shangjianmab (Beijing) Biotechnology Co., Ltd., established on 2016-10-31, Business scope includes biomedicine,technology development in biotechnology,technical consulting,technology transfer,Technical Services;Medical Research and Experimental Development;Import and export;Technology Import and Export.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Meiji Seika Pharma Co., Ltd. engages in the business of manufacture and distribution of pharmaceutical products. It also engages in the animal health business. The company was founded on October 9, 1916 and is headquartered in Tokyo, Japan.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Peking Union Medical College Hospital, also known as Beijing Xiehe Hospital (Chinese: 北京协和医院), is a renowned general hospital in Beijing, China. It was founded in 1921 by Rockefeller Foundation and is affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS). During the Cultural Revolution, it was renamed the "Anti-imperialist Hospital".

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver. Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has a track record supporting clinical studies across diverse therapeutic areas and routes of administration. Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics.